External beam radiation therapy (EBRT) is a form of radiation therapy in which radiation from a source outside the body is directed toward a defined treatment region. It is used principally to treat cancer, either to eradicate disease, reduce the likelihood of recurrence, or relieve symptoms. Unlike brachytherapy, which places radioactive sources within or immediately beside the treatment site, and radionuclide therapy, which administers radioactive substances, EBRT delivers its therapeutic radiation across a distance from an external machine.
The treatment depends on a controlled difference between the radiation response of the target and that of surrounding normal tissues. Modern systems combine three-dimensional imaging, computerized dose calculation, shaped radiation fields, and verification of patient position. Treatment may involve a single exposure or a course of repeated exposures, called fractions. Its effects depend not only on total dose but also on the dose per fraction, the volume irradiated, treatment timing, radiation type, and the biology of the tissues involved.
EBRT is therefore both a clinical treatment and a precision engineering process. Its practice brings together radiation oncology, medical physics, imaging, dosimetry, and radiation therapy technology, with distinct responsibilities for prescription, planning, delivery, and quality assurance.
Radiation sources and physical dose distribution
The most widely used EBRT machine is the medical linear accelerator, commonly abbreviated to linac. It accelerates electrons using microwave electromagnetic fields. For photon treatment, the electrons strike a metal target, producing a broad spectrum of high-energy X-rays through bremsstrahlung. For electron treatment, the target is removed from the beam path and the electron beam is shaped for direct use. Common clinical photon beam designations include 6 and 10 megavolts; these describe the nominal accelerating potential rather than a single photon energy.
High-energy photons penetrate tissue and deposit energy mainly by setting secondary electrons in motion. Their depth–dose distribution includes a buildup region beneath the surface, followed by a gradual decline with depth. This buildup can reduce skin dose relative to the maximum dose deeper in tissue, although the actual surface dose depends on beam energy, field arrangement, accessories, and patient anatomy. Multiple beams entering from different directions can concentrate their overlapping high-dose regions in the target while distributing entrance and exit doses through surrounding tissues. No photon arrangement eliminates irradiation outside the target.
Electron beams have a more limited useful range and a comparatively rapid dose falloff beyond that range. They are therefore used for selected superficial targets, including some skin lesions and shallow postoperative regions. Their behavior is sensitive to surface irregularities and changes in tissue density. A tissue-equivalent material called bolus can be placed on the skin to alter buildup or bring the effective high-dose region closer to the surface. Bolus is also used with photon treatments when adequate surface dose is required.
Proton therapy and other charged-particle treatments use different depth–dose properties. Protons deposit a relatively large amount of energy near the end of their range, producing a Bragg peak. Combining proton energies spreads this peak across the target depth. This can reduce dose beyond the target compared with many photon arrangements, but the stopping position depends on the tissues traversed. Changes in anatomy, motion, and uncertainties in converting imaging information into stopping power can therefore affect the delivered distribution. Carbon-ion treatment additionally involves biological effects that differ more substantially from those of conventional photons.
Some facilities use cobalt-60 machines, which generate gamma rays through radioactive decay rather than electrical acceleration. Their source output declines with a half-life of approximately 5.27 years, requiring allowance for decay and eventual source replacement. Across all these technologies, absorbed dose is expressed in the gray, symbol Gy, where . Beam energy, absorbed dose, and biological effect are related but are not interchangeable quantities.
Cellular effects and the biological basis of fractionation
The therapeutic action of ionizing radiation begins with energy deposition in cells and their surroundings. Radiation can damage DNA directly or indirectly through reactive products formed by the irradiation of water. DNA double-strand breaks are particularly important because inaccurate repair or failure to repair them can prevent continued cell reproduction. A cell need not disappear immediately after exposure for treatment to be effective: it may retain metabolic activity yet lose the capacity to generate a viable lineage.
Radiation response varies with DNA repair capacity, cell-cycle state, oxygen availability, and the tissue environment. Oxygen can make certain radiation-induced molecular changes less chemically reversible, increasing the effectiveness of low-linear-energy-transfer radiation such as conventional X-rays. Poorly oxygenated tumor regions may consequently be more resistant. The magnitude of this effect differs with radiation quality and biological conditions; it is not a fixed property of every tumor. High-linear-energy-transfer radiation creates denser tracks of ionization and generally shows less dependence on oxygen.
Fractionation divides a treatment into separate exposures. Its biological rationale is traditionally described through repair of sublethal damage, redistribution of cells through the cell cycle, reoxygenation of previously hypoxic regions, and repopulation. These processes affect tumors and normal tissues differently. Time between fractions can permit normal-tissue repair, but prolonging the overall course can also allow surviving tumor cells to multiply. In some rapidly proliferating cancers, treatment interruptions are therefore clinically important rather than merely logistical events.
A widely used representation of cell survival is the linear–quadratic model:
where is the surviving fraction, is dose, and and describe components of radiation sensitivity. For equal fractions with adequate repair between exposures, a commonly used biologically effective dose expression is
where is the number of fractions and is dose per fraction. These expressions provide a framework for comparing schedules, not an exact prediction for an individual patient. Additional corrections may be needed for treatment duration, incomplete repair, or other biological circumstances.
Late-responding normal tissues often have a lower estimated ratio than many rapidly proliferating tumors, making them particularly sensitive to increases in fraction size. Important exceptions complicate any simple tumor-versus-normal-tissue distinction: prostate cancer, for example, has substantial clinical evidence supporting sensitivity to fraction size. Model assumptions become especially consequential when extrapolating to very large fractions. Clinical outcomes and measured normal-tissue effects remain necessary to establish whether a proposed schedule has an acceptable therapeutic balance.
Clinical purposes and integration with other treatments
EBRT can be definitive, meaning it is a principal treatment intended to achieve durable tumor control without surgical removal of the entire primary lesion. Established examples include selected cancers of the prostate, head and neck, cervix, and lung. The choice of treatment depends on tumor type, anatomical extent, functional consequences, and other clinical characteristics. Cancer staging, pathological findings, imaging, and the patient's general condition help define both the treatment goal and the volume requiring irradiation.
In other settings, radiation complements surgery. Postoperative irradiation treats regions at risk of microscopic residual disease after an operation. In breast cancer, irradiation after breast-conserving surgery is an established component of treatment for many patients. Preoperative irradiation is used in selected diseases, including rectal cancer and some soft-tissue sarcomas, where it can improve local disease management or alter the conditions for resection. Timing also changes which tissues are exposed and how treatment interacts with wound healing.
Radiation can be combined with chemotherapy or other systemic treatments. Concurrent chemoradiation is established in several cancers because particular drugs increase radiation sensitivity or address disease outside the radiation field. The same interaction may increase normal-tissue toxicity, so the combination is not simply the sum of two independent treatments. Cervical cancer illustrates the distinction between modalities: definitive treatment commonly combines external beam chemoradiation with brachytherapy, which supplies a concentrated additional dose to the primary region. EBRT alone does not reproduce that brachytherapy distribution.
Palliative EBRT aims to relieve symptoms or prevent local complications rather than eradicate all disease. It can reduce pain from bone metastases, control bleeding from some tumors, or treat selected lesions causing obstruction or neurological compromise. These uses belong within palliative care but are not restricted to the final days of life. Symptom relief may occur over days or weeks, depending on the condition. Treatment schedules are often shorter than curative courses because the balance includes treatment burden, speed of benefit, and the likelihood of needing retreatment.
A separate group of applications includes total-body irradiation as part of selected conditioning regimens for hematopoietic stem cell transplantation, and treatment of certain nonmalignant disorders, such as heterotopic ossification or selected benign intracranial lesions. These indications have different dose ranges and treatment objectives from conventional solid-tumor radiotherapy. Localized treatment of a limited number of metastatic sites is also used in selected clinical settings, but its value depends on the primary cancer, disease distribution, systemic treatment options, and the evidence for that particular situation.
Simulation, target definition, and treatment planning
Planning begins with simulation: establishing a reproducible treatment position and obtaining images in that position. Computed tomography is the principal planning dataset for many treatments because it provides three-dimensional anatomy and information used to calculate radiation transport through tissue. Immobilization devices may include molded cushions, thermoplastic masks, or customized supports. Their purpose is to reduce positional variation while allowing the intended treatment arrangement to be repeated over the course.
Other imaging can clarify boundaries that are poorly defined on CT. Magnetic resonance imaging provides soft-tissue detail, while positron emission tomography can contribute information about metabolically active disease. Combining datasets requires image registration, whose accuracy must be assessed rather than assumed. Different patient positions, bladder filling, breathing phases, or intervals between scans can create discrepancies. Images are interpreted alongside operative findings, histopathology, and other clinical information; a visible abnormality is not automatically identical to the full treatment target.
Target volumes distinguish different kinds of uncertainty. The gross tumor volume represents demonstrable disease. The clinical target volume includes tissue judged at risk of microscopic involvement. An internal target volume may account for internal movement or variation, such as respiratory displacement. A planning target volume adds a geometrical allowance intended to maintain adequate coverage despite specified positioning and motion uncertainties. These volumes serve different purposes: a planning margin is not evidence that tumor actually occupies the entire expanded region. Proton plans may additionally use explicit robustness analysis for setup and range uncertainties.
Organs at risk are outlined so that their dose can be evaluated and constrained. The significance of exposure depends on both the dose and its spatial distribution. For structures such as the spinal cord, a high dose to a small region can be especially important; for organs such as the lungs, the volume receiving various dose levels is also central. A dose–volume histogram summarizes how much of a structure receives a specified dose, but it does not show where within that structure the dose lies. Spatial review of the plan remains essential.
Dose calculation uses models of radiation interaction, ranging from simplified algorithms to detailed transport methods such as Monte Carlo simulation. Inverse planning uses mathematical optimization to search for beam intensities or machine settings that satisfy competing objectives. A mathematically improved score does not necessarily establish clinical superiority: target coverage, organ exposure, robustness, treatment complexity, and practical deliverability all matter. The final plan translates a clinical prescription into machine instructions, with documented acceptance of the resulting trade-offs.
Conformal delivery, image guidance, and adaptation
Three-dimensional conformal radiotherapy shapes a limited number of fields around the target using anatomical imaging. A multileaf collimator, consisting of independently movable shielding leaves, forms the beam aperture. Intensity-modulated radiation therapy (IMRT) goes further by varying intensity across each field, allowing complex high-dose shapes and greater avoidance of nearby structures. This can be particularly useful when a target wraps around an organ at risk, although increased conformity may be accompanied by a broader distribution of lower doses.
Volumetric modulated arc therapy delivers intensity-modulated treatment while the gantry rotates around the patient. Leaf positions, dose rate, and gantry speed can change during delivery. Helical systems combine rotation with longitudinal movement of the treatment couch. Different platforms can produce clinically suitable plans, and machine design alone does not establish which plan is best for a particular anatomy. Treatment quality depends on planning choices, commissioning, verification, and the relationship between the target and nearby tissues.
Image-guided radiation therapy checks the treatment position using images obtained near or during delivery. Methods include planar X-rays, cone-beam CT, implanted fiducial markers, ultrasound, and MRI integrated with the treatment system. Imaging may identify a shift that is corrected by moving the couch, or it may reveal a change that requires more substantial review. Alignment to bone is not always an adequate substitute for alignment to a mobile internal organ. Imaging frequency and method therefore depend on the target and the treatment's sensitivity to error.
Motion management addresses changes during irradiation as well as differences between appointments. Four-dimensional CT samples respiratory motion across phases of breathing. Breath-hold, respiratory gating, abdominal compression, and tumor tracking can each reduce or accommodate motion under appropriate conditions. Deep-inspiration breath-hold in selected left-sided breast treatments can increase separation between the heart and the treated chest region. For scanned particle beams and highly modulated delivery, movement can also interact with the changing beam pattern, producing an interplay effect that must be considered.
Adaptive radiotherapy modifies treatment in response to anatomical or other relevant changes. Offline adaptation revises a plan between appointments; online adaptation creates or selects a suitable plan during the treatment visit. Triggers can include weight loss, tumor shrinkage, altered organ filling, or changed relationships between the target and sensitive structures. Adaptation requires renewed checks of image interpretation, contours, dose calculation, and deliverability. Greater capacity to change a plan creates additional verification tasks rather than removing the need for margins and quality assurance.
Dose schedules and stereotactic treatment
A radiation prescription specifies more than a total number of grays. It includes the dose per fraction, number of fractions, intended target, overall timing, and the dose distribution required for treatment acceptance. Historically, many conventionally fractionated adult curative courses used approximately 1.8–2 Gy per fraction, commonly delivered on five days each week. Total doses differ substantially among diseases and treatment settings. A postoperative breast course, definitive head-and-neck treatment, and palliative treatment of a bone metastasis cannot be compared meaningfully by total physical dose alone.
Hypofractionation uses fewer, larger fractions; hyperfractionation uses smaller fractions, usually more than once per day. Accelerated treatment shortens overall treatment time and is conceptually distinct from either approach, although schedules can combine these features. The consequences depend on repair, repopulation, fraction-size sensitivity, and the organs exposed. Shorter courses can reduce travel and machine occupancy, but convenience is not the biological basis for assuming equivalence. Disease-specific comparative studies are needed to establish suitable schedules.
Breast radiotherapy provides a well-studied example of changing fractionation practice. Moderate hypofractionation, including schedules such as 40 Gy in 15 fractions, became established through large trials. The FAST-Forward trial, reported in 2020, supported 26 Gy in five fractions over one week as an alternative to 40 Gy in 15 fractions for many patients receiving postoperative local breast irradiation. Its findings concern a defined population, technique, and follow-up period; they do not establish that five-fraction treatment is interchangeable with longer schedules for every breast treatment volume or clinical circumstance.
Stereotactic radiosurgery delivers highly focused radiation to intracranial targets, traditionally in one fraction, without a surgical incision. Related intracranial treatments use several fractions when target size or proximity to sensitive structures makes fractionation important. Stereotactic body radiation therapy, also called stereotactic ablative radiotherapy, extends high-precision, high-dose-per-fraction treatment to extracranial sites. Established applications include selected early-stage lung cancers, particularly when surgery is not performed, and selected primary or metastatic lesions elsewhere.
Stereotactic treatment depends on steep dose gradients, accurate localization, immobilization, and attention to motion. A small geometric error can matter greatly when the prescription falls rapidly over a few millimeters. Dose constraints are specific to the number of fractions and the structure involved; constraints developed for conventional fractionation cannot simply be copied into a stereotactic plan. Conversely, some palliative treatments intentionally use straightforward arrangements rather than stereotactic complexity. A single 8 Gy fraction is an established option for many uncomplicated painful bone metastases, although retreatment is more frequent than after some multifraction regimens.
Treatment delivery, dosimetry, and safety systems
A treatment course involves several professional groups with overlapping checks but distinct responsibilities. The radiation oncologist establishes the clinical indication, prescription, and target interpretation. Medical physicists oversee the physical accuracy and safe technical performance of treatment systems. Dosimetrists or other trained planning staff develop plans within the local professional framework, while radiation therapists or therapeutic radiographers position patients, operate treatment equipment, and monitor delivery. Nurses and other clinicians assess treatment effects and supportive-care needs.
Before a machine is used clinically, acceptance testing and commissioning establish whether it performs as specified and whether its behavior is correctly represented in the planning system. Radiation dosimetry connects machine output with absorbed dose through calibrated instruments and measurement protocols. Routine quality assurance checks output stability, mechanical alignment, imaging geometry, safety interlocks, and other parameters. The tolerance appropriate to a simple field may not be adequate for a small stereotactic target or a highly modulated plan.
Plan-specific checks assess whether the intended treatment has been transferred and can be delivered correctly. Depending on the technique, these can include independent dose calculations, phantom measurements, verification of monitor units, and review of treatment parameters. End-to-end tests assess a complete chain—from imaging and planning to positioning and irradiation—rather than testing each component in isolation. Record-and-verify systems help enforce approved settings, but their protection depends on correct data, appropriate configuration, and the ability to recognize an unexpected result.
At each treatment visit, identity, site, position, accessories, and relevant imaging are checked. The patient is usually alone in a shielded treatment room during beam delivery, with audiovisual monitoring from the control area. The irradiation itself is not normally felt. Setup and verification can take longer than the beam-on interval, particularly for complex or adaptive treatments. Conventional external beam treatment does not leave a radioactive source in the body and does not make the patient radioactive.
Patient safety also depends on organizational design. Laterality errors, incorrect prescriptions, data-transfer failures, and misinterpretation of imaging are not prevented solely by precise machinery. Standardized workflows, peer review, independent checks, incident learning, and clearly defined responses to interruptions address different failure modes. Reirradiation adds particular complexity because previous dose distributions, anatomical changes, fractionation, and elapsed time must be considered together. Summing old and new plans can be uncertain when organs have moved or changed shape; a numerical composite does not remove those uncertainties.
Acute effects, late effects, and functional outcomes
Adverse effects depend strongly on which tissues receive radiation, the dose distribution, fractionation, concurrent treatments, and individual susceptibility. EBRT is primarily a local or regional treatment: a pelvic field does not ordinarily cause scalp hair loss, and a brain field does not directly expose the bowel. General symptoms such as fatigue can nevertheless occur during a course. The severity and timing of effects vary, and the absence of immediate symptoms does not imply that no biological effect has occurred.
Acute reactions develop during treatment or in the following weeks, particularly in tissues with rapidly renewing cells. Examples include skin erythema, oral or pharyngeal mucositis, swallowing discomfort, and gastrointestinal irritation when the relevant organs are irradiated. Exposure of substantial amounts of active bone marrow can affect blood-cell production, especially with concurrent systemic therapy. Some acute reactions peak after the final fraction because the tissue response continues after irradiation has stopped. Many improve as surviving stem and progenitor cells restore tissue function.
Late effects can emerge months or years later and may be persistent. Their mechanisms include vascular injury, depletion or dysfunction of tissue-specific cells, chronic inflammatory signaling, and fibrosis. Depending on the site, clinically important outcomes can include salivary dysfunction, bowel or urinary changes, endocrine insufficiency, altered sexual function, or lymphedema. Radiation pneumonitis can occur after thoracic irradiation, while later lung changes may include fibrosis. Surgery, systemic drugs, pre-existing disease, and radiation may contribute jointly, making attribution to a single cause difficult.
Some organs have particular long-term vulnerabilities. Radiation involving the hypothalamic–pituitary region can affect hormonal regulation. Exposure of the developing brain can influence cognition, with risks shaped by age, volume, dose, and other treatments. Cardiac exposure during thoracic treatment is relevant to later cardiovascular outcomes, which is one reason contemporary planning seeks to reduce heart dose where feasible. Childhood treatment requires special attention to growth and development, and irradiation of reproductive organs can affect fertility. These outcomes are not uniform consequences of all EBRT courses.
Radiation can also increase the long-term risk of a second malignancy, usually considered over years to decades rather than during treatment. Risk depends on age at exposure, tissue, dose distribution, inherited susceptibility, and competing health risks. Follow-up studies must distinguish treatment effects from background cancer risk and shared exposures. Evaluation therefore extends beyond tumor control to organ function, health-related quality of life, and patient-reported outcomes. These measures can reveal persistent effects not fully captured by clinician grading or imaging alone.
Historical development, clinical evidence, and access
The therapeutic use of X-rays began soon after Wilhelm Röntgen's discovery in 1895. Early treatments relied on low-energy equipment and limited knowledge of dose, tissue tolerance, and radiation protection. Such beams deposited substantial dose near the surface and were less suited to deep targets than later megavoltage systems. Clinical cobalt-60 units entered use in 1951, and medical linear accelerators entered clinical service during the 1950s. These developments made deep treatment more practical and supported increasingly reproducible dose delivery.
Subsequent progress depended as much on imaging and computation as on radiation production. CT-based planning made it possible to represent targets and organs in three dimensions rather than infer their position primarily from projection images and external landmarks. Computer-controlled multileaf collimators, inverse planning, and integrated imaging enabled increasingly conformal treatments. Proton therapy developed from early treatments at research accelerators into hospital-based programs, while stereotactic techniques evolved from rigid frame-based localization toward a variety of image-guided systems.
Clinical progress is established through outcomes rather than geometric precision alone. A more conformal plan may reduce a particular organ dose without necessarily improving survival, and a technically elaborate treatment may not outperform a simpler one for every indication. Randomized controlled trials have established important roles for postoperative irradiation, concurrent chemoradiation, altered fractionation, and selected stereotactic treatments. The relevant endpoints differ: local control, survival, symptom relief, treatment toxicity, and preservation of function answer related but distinct questions.
Comparative evidence for technologies can be difficult to interpret. Patients referred for a specialized platform may differ in age, prognosis, tumor location, or access to other care. Observational comparisons therefore require attention to selection bias and confounding. Proton therapy offers clear physical opportunities to reduce dose outside a target, particularly in selected pediatric and anatomically challenging cases, but the size of the resulting clinical benefit is disease- and endpoint-specific. A general physical advantage does not establish universal superiority over contemporary photon treatment.
Access depends on more than purchasing a machine. Safe services require trained personnel, reliable electricity, shielding, maintenance, imaging, treatment planning, dosimetry, and functioning referral pathways. Equipment downtime and workforce shortages can limit treatment capacity even where machines are installed. Travel and repeated attendance create additional barriers, linking fractionation choices and service organization to health equity. Current research includes automated planning, adaptive delivery, improved motion management, and ultra-high-dose-rate approaches known as FLASH radiotherapy. FLASH has shown normal-tissue-sparing effects in some preclinical settings, but its clinical application remains investigational, with unresolved questions about dose, timing, beam characteristics, and reproducible biological effects.